Current Bladder Dysfunction Reports

, Volume 13, Issue 4, pp 274–281 | Cite as

Detrusor Underactivity and Bladder Outlet Procedures in Men

  • Shu-Yu Wu
  • Yuan-Hong Jiang
  • Hann-Chorng KuoEmail author
Reconstructed Bladder Function & Dysfunction (M Kaufman, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Reconstructed Bladder Function & Dysfunction


Purpose of Review

Detrusor underactivity (DU) is a common but poorly understood clinical problem. The diagnosis and treatment of DU are difficult and full of uncertainties. There are many overlaps between DU and bladder outlet obstruction (BOO) in clinical symptoms and managements. In this review, we discuss the relationship of clinical diagnosis and treatment between DU and BOO in men, especially the outcome of bladder outlet surgery in patients with DU.

Recent Findings

DU could be resulted from many different etiologies, including psychogenic, neurogenic, myogenic, and the reduced detrusor contractility after increasing muscle work against the increase of bladder outlet resistance. Current managements are usually focused on relieving voiding difficulty and prevent urine retention to avoid urinary tract infection and upper urinary tract deterioration. Since there is no suitable medical treatment to enhance bladder contractility, most of the researches focus on reducing bladder outlet resistance and treat BOO. Many recent studies have reported the therapeutic outcome of transurethral incision of the bladder neck, transurethral resection of the prostate and urethral sphincter botulinum toxin A injection.


The current treatment options in DU are limited. Even if there are many clinical trials revealing good results in patients with DU after BOO surgery, the evidence that BOO surgeries benefit patients with DU are still controversial. The actual mechanism of detrusor function recovery after BOO surgery in men with DU has not been well elucidated. Nevertheless, a portion of men with DU can safely and effectively improve their voiding symptoms and voiding efficiency after BOO surgeries. Further research of the underlying pathophysiology between DU and BOO is mandatory.


Benign prostatic hyperplasia Bladder outlet obstruction Detrusor underactivity Lower urinary tract symptoms 


Compliance with Ethical Standards

Conflict of Interest

Shu-Yu Wu declares that he has no conflict of interest.

Yuan-Hong Jiang declares that he has no conflict of interest.

Hann-Chorng Kuo declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. Standardisation sub-committee of the international continence society. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21:167–78.CrossRefGoogle Scholar
  2. 2.
    •• Chapple CR, Osman NI, Birder L, van Koeveringe GA, Oelke M, Nitti VW, et al. The underactive bladder: a new clinical concept? Eur Urol. 2015;68:351–3. A comprehensive review of bladder underactivity, with international expert group presents a working definition for the symptoms that characterise bladder underactivity, with the aim of facilitating further research in this area. CrossRefGoogle Scholar
  3. 3.
    Resnick NM, Yalla SV, Laurino E. The pathophysiology of urinary incontinence among institutionalized elderly persons. N Engl J Med. 1989;320:1–7.CrossRefGoogle Scholar
  4. 4.
    Miyazato M, Yoshimura N, Chancellor MB. The other bladder syndrome: underactive bladder. Rev Urol. 2013;15:11–22.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Andersson KE. Detrusor underactivity/underactive bladder: new research initiatives needed. J Urol. 2010;184:1829–30.CrossRefGoogle Scholar
  6. 6.
    Stocchi F, Carbone A, Inghilleri M, Monge A, Ruggieri S, Berardelli A, et al. Urodynamic and neurophysiological evaluation in Parkinson’s disease and multiple system atrophy. J Neurol Neurosurg Psychiatry. 1997;62:507–11.CrossRefGoogle Scholar
  7. 7.
    • Juszczak K, Drewa T. Pharmacotherapy in detrusor underactivity: a new challenge for urologists and pharmacologists (from lab to clinic). Pharmacol Rep. 2016;68:703–6. A review of the potential pharmacological targets in DU treatment in the animal model. The potential pharmacological targets in DU therapy were discussed, such as bombesin receptors, prostaglandin-, ATP-, NO-, CGRP-, SP-, Dopamine-, NGF-, M2-, and agrin-dependent pathways. CrossRefGoogle Scholar
  8. 8.
    Suskind AM, Smith PP. A new look at detrusor underactivity: impaired contractility versus afferent dysfunction. Curr Urol Rep. 2009;10:347–51.CrossRefGoogle Scholar
  9. 9.
    Brierly RD, Hindley RG, McLarty E, Harding DM, Thomas PJ. A prospective controlled quantitative study of ultrastructural changes in the underactive detrusor. J Urol. 2003;169:1374–8.CrossRefGoogle Scholar
  10. 10.
    Saito M, Yokoi K, Ohmura M, Kondo A. Effects of partial outflow obstruction on bladder contractility and blood flow to the detrusor: comparison between mild and severe obstruction. Urol Int. 1997;59:226–30.CrossRefGoogle Scholar
  11. 11.
    Araki I, Kitahara M, Oida T, Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. J Urol. 2000;164:1640–3.CrossRefGoogle Scholar
  12. 12.
    Burney TL, Senapati M, Desai S, Choudhary ST, Badlani GH. Acute cerebrovascular accident and lower urinary tract dysfunction: a prospective correlation of the site of brain injury with urodynamic findings. J Urol. 1996;156:1748–50.CrossRefGoogle Scholar
  13. 13.
    Smith PP. Aging and the underactive detrusor: a failure of activity or activation? Neurourol Urodyn. 2010;29:408–12.PubMedGoogle Scholar
  14. 14.
    •• Smith PP, Chalmers DJ, Feinn RS. Does defective volume sensation contribute to detrusor underactivity? Neurourol Urodyn. 2015;34:752–6. The urodynamic finding of detrusor underactivity (DU) in neurologically intact unobstructed patients revealed that diminished central sensitivity to volume afferent activity contributes to DU. CrossRefGoogle Scholar
  15. 15.
    •• Jiang YH, Kuo HC. Urothelial barrier deficits, suburothelial inflammation and altered sensory protein expression in detrusor underactivity. J Urol. 2017;197:197–203. A comprehensive human study of urothelial dysfunction in patients with DU, revealed that urothelial dysfunction, increased suburothelial inflammation and altered sensory protein expressions in bladder mucosa were prominent in patients with DU. Impaired urothelial signaling and sensory transduction pathways appear to reflect the pathophysiology of DU. CrossRefGoogle Scholar
  16. 16.
    • Yang TH, Chuang FC, Kuo HC. Urodynamic characteristics of detrusor underactivity in women with voiding dysfunction. PLoS One. 2018;13:e0198764. A large cohort of women with voiding dysfunction revealed that bladder contractility index and voiding efficiency were significantly lowest in DU patients than normal tracing group. Reduced bladder sensation was noted in DU and negatively associated with detrusor contractility. CrossRefGoogle Scholar
  17. 17.
    Lee WC, Wu HP, Tai TY, Liu SP, Chen J, Yu HJ. Effects of diabetes on female voiding behavior. J Urol. 2004;172:989–92.CrossRefGoogle Scholar
  18. 18.
    Chuang FC, Kuo HC. Management of lower urinary tract dysfunction after radical hysterectomy with or without radiotherapy for uterine cervical cancer. J Formos Med Assoc. 2009;108:619–26.CrossRefGoogle Scholar
  19. 19.
    Matsukawa Y, Hattori R, Komatsu T, Funahashi Y, Sassa N, Gotoh M. De novo detrusor underactivity after laparoscopic radical prostatectomy. Int J Urol. 2010;17:643–8.CrossRefGoogle Scholar
  20. 20.
    • Jiang YH, Liao CH, Kuo HC. Role of bladder dysfunction in men with lower urinary tract symptoms refractory to alpha-blocker therapy: a video-urodynamic analysis. Low Urin Tract Symptoms. 2018;10:32–7. A clinical study of 2991 men with LUTS revealed that one-third of male LUTS was due to bladder dysfunction. A man older than 70 years with LUTS and total prostate volume less than 30 mL usually indicates the presence of bladder dysfunction rather than BOO. CrossRefGoogle Scholar
  21. 21.
    Abrams P. Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function. BJU Int. 1999;84:14–5.CrossRefGoogle Scholar
  22. 22.
    •• Jiang YH, Kuo HC. Video-urodynamic characteristics of non-neurogenic, idiopathic underactive bladder in men – a comparison of men with normal tracing and bladder outlet obstruction. PLoS One. 2017;12:e0174593. This study analyzed the video-urodynamic study characteristics of patients with underactive bladder in a large cohort of men with lower urinary tract symptoms (LUTS). VUDS findings in DU patients showed a slowly increased detrusor pressure, intermittent detrusor contractions, or early decline of detrusor contraction, resulting in a low maximum flow rate , and large PVR. CrossRefGoogle Scholar
  23. 23.
    Levin RM, Longhurst PA, Barasha B, McGuire EJ, Elbadawi A, Wein AJ. Studies on experimental bladder outlet obstruction in the cat: long-term functional effects. J Urol. 1992;148:939–43.CrossRefGoogle Scholar
  24. 24.
    Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated bladder outlet obstruction. BJU Int. 2005;96:1301–6.CrossRefGoogle Scholar
  25. 25.
    •• Rademakers KL, van Koeveringe GA, Oelke M. Detrusor underactivity in men with lower urinary tract symptoms/benign prostatic obstruction: characterization and potential impact on indications for surgical treatment of the prostate. Curr Opin Urol. 2016;26:3–10. A comprehensive review of DU in men with LUTS. The authors point out careful assessment of voiding dysfunction to differential diagnosis between DU and BOO is important, and should be done with pressure flow study. CrossRefGoogle Scholar
  26. 26.
    Barendrecht MM, Oelke M, Maria P. Is the use of parasympathomimetics for treating an underactive urinary bladder evidence-based? BJU Int. 2007;99:749–52.CrossRefGoogle Scholar
  27. 27.
    Chancellor MB, Kaufman J. Case for pharmacotherapy development for underactive bladder. Urology. 2008;72:966–7.CrossRefGoogle Scholar
  28. 28.
    Yamanishi T, Yasuda K, Kamai T, Tsujii T, Sakakibara R, Uchiyama T, et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int J Urol. 2004;11:88–96.CrossRefGoogle Scholar
  29. 29.
    •• Jiang YH, Wang CC, Kuo HC. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment. PLoS One. 2018;13:e0190704. This study analyzed the underlying lower urinary tract dysfunctions by video-urodynamic studies in men who have persistent storage symptoms after initial drug therapy for LUTS suggestive of BPH. In men who have persistent storage symptoms after medical treatment for LUTS/BPH, BOO should be carefully investigated and appropriate management being given to improve LUTS. CrossRefGoogle Scholar
  30. 30.
    Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int. 2004;93:745–50.CrossRefGoogle Scholar
  31. 31.
    Thomas AW, Cannon A, Bartlett E, Ellis-Jones J, Abrams P. The natural history of lower urinary tract dysfunction in men: minimum 10-year urodynamic follow-up of untreated detrusor underactivity. BJU Int. 2005;96:1295–300.CrossRefGoogle Scholar
  32. 32.
    Han DH, Jeong YS, Choo MS, Lee KS. The efficacy of transurethral resection of the prostate in the patients with weak bladder contractility index. Urology. 2008;71:657–61.CrossRefGoogle Scholar
  33. 33.
    Ou R, Pan C, Chen H, Wu S, Wei X, Deng X, et al. Urodynamically diagnosed detrusor hypocontractility: should transurethral resection of the prostate be contraindicated? Int Urol Nephrol. 2012;44:35–9.CrossRefGoogle Scholar
  34. 34.
    Masumori N, Furuya R, Tanaka Y, Furuya S, Ogura H, Tsukamoto T. The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery. BJU Int. 2010;105:1429–33.CrossRefGoogle Scholar
  35. 35.
    Al-Hayek S, Thomas A, Abrams P. Natural history of detrusor contractility- minimum ten-year urodynamic follow-up in men with bladder outlet obstruction and those with detrusor. Scand J Urol Nephrol Suppl. 2004;215:101–8.CrossRefGoogle Scholar
  36. 36.
    Chen YC, Wang CC, Kuo HC. Therapeutic effects of transurethral incision of the bladder neck on primary bladder neck dysfunction refractory to alpha-adrenergic blockade in men. Formosan Journal of Surgery. 2012;45:78–82.CrossRefGoogle Scholar
  37. 37.
    Kim M, Jeong CW, Oh SJ. Effect of preoperative urodynamic detrusor underactivity on transurethral surgery for benign prostatic hyperplasia: a systematic review and meta-analysis. J Urol. 2018;199:237–44.CrossRefGoogle Scholar
  38. 38.
    Lee KH, Kuo HC. Bladder function recovery after treatment in male patients with detrusor underactivity – clinical results and predictive factors. J Urol. 2017;197(Suppl 4S):e748.CrossRefGoogle Scholar
  39. 39.
    • Woo MJ, Ha YS, Lee JN, Kim BS, Kim HT, Kim TH, et al. Comparison of surgical outcomes between holmium laser enucleation and transurethral resection of the prostate in patients with detrusor underactivity. Int Neurourol J. 2017;21:46–52. The study reports that HoLEP can be effectively and safely performed in patients with BPH and clinically DU. The therapeutic outcome was better than TURP in DU patients. CrossRefGoogle Scholar
  40. 40.
    Cho MC, Ha SB, Park J, Son H, Oh SJ, Kim SW, et al. Impact of detrusor underactivity on surgical outcomes of laser prostatectomy: comparison in serial 12-month follow-up outcomes between potassium-titanyl-phosphate photoselective vaporization of the prostate (PVP) and holmium laser enucleation of the prostate (HoLEP). Urology. 2016;91:158–66.CrossRefGoogle Scholar
  41. 41.
    • Cho MC, Park J, Kim JK, Cho SY, Jeong H, Oh SJ, et al. Can preoperative detrusor underactivity influence surgical outcomes of 120 W HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP)? A serial 3-year follow-up study. Neurourol Urodyn. 2018;37:407–16. Improvements in LUTS, Qmax, and bladder voiding efficiency (BE) can maintain up to 3 years after HPS vaporization of the prostate (PVP) or holmium laser enucleation of the prostate (HoLEP) for LUTS/BPH, irrespective of the presence or absence of preoperative DU. However, there was no difference in improvement of QOL or Qmax or BVE between PVP and HoLEP. CrossRefGoogle Scholar
  42. 42.
    • Jiang YH, Jhang JF, Chen SF, Kuo HC. Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Low Urin Tract Symptoms. 2017. This clinical trial revealed that urethral sphincter injection of onabotulinumtoxinA is effective in 60% of patients with DU. Careful videourodynamic interpretation of bladder neck opening enables urologists to select appropriate candidates for onabotulinumtoxinA treatment.
  43. 43.
    Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol. 2004;171:2128–37.CrossRefGoogle Scholar
  44. 44.
    Mehta S, Hill D, Foley N, Hsieh J, Ethans K, Potter P, et al. A meta-analysis of botulinum toxin sphincteric injections in the treatment of incomplete voiding after spinal cord injury. Arch Phys Med Rehabil. 2012;93:597–603.CrossRefGoogle Scholar
  45. 45.
    •• Jiang YH, Lee CL, Jhang JF, Kuo HC. Current pharmacological and surgical treatment of underactive bladder. Ci Ji Yi Xue Za Zhi. 2017;29:187–91. This is a comprehensive review of current treatment strategy. Treatment of UAB or DU aims to reduce the postvoid residual urine volume and increase voiding efficiency, either by spontaneous voiding or abdominal straining. Pharmacotherapy with parasympathomimetics or cholinesterase inhibitors might be tried, and benefits can be achieved in combination with alpha-blockers. Bladder outlet surgeries, including urethral onabotulinumtoxinA injection, transurethral incision of the bladder neck, and transurethral incision or resection of the prostate can effectively improve voiding efficiency and decrease the PVR in most patients with DU. PubMedPubMedCentralGoogle Scholar
  46. 46.
    Kuo HC. Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003;170:1908–12.CrossRefGoogle Scholar
  47. 47.
    Kuo HC. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology. 2003;61:550–4.CrossRefGoogle Scholar
  48. 48.
    Kuo HC. Recovery of detrusor function after urethral botulinum A toxin injection in patients with idiopathic low detrusor contractility and voiding dysfunction. Urology. 2007;69:57–61.CrossRefGoogle Scholar
  49. 49.
    •• Jiang YH, Wang CC, Kuo HC. OnabotulinumtoxinA urethral sphincter injection as treatment for non-neurogenic voiding dysfunction – a randomized, double-blind, placebo-controlled study. Sci Rep. 2016;6:38905. This randomized, double-blind, placebo-controlled trial was designed to determine the clinical efficacy of onabotulinumtoxinA urethral sphincter injections in patients with dysfunctional voiding or detrusor underactivity. For patients with non-neurogenic voiding dysfunction, the success rate of onabotulinumtoxinA urethral sphincter injection was not superior to placebo. Repeat urethral sphincter onabotulinumtoxinA injections offered greater therapeutic effects in both dysfunctional voiding and detrusor underactivity patients. CrossRefGoogle Scholar
  50. 50.
    Kanai A, Andersson KE. Bladder afferent signaling: recent findings. J Urol. 2010;183:1288–95.CrossRefGoogle Scholar
  51. 51.
    Pizzi A, Falsini C, Martini M, Rossetti MA, Verdesca S, Tosto A. Urinary incontinence after ischemic stroke: clinical and urodynamic studies. Neurourol Urodyn. 2014;33:420–5.CrossRefGoogle Scholar
  52. 52.
    •• Jiang YH, Chen SF, Jhang JF, Kuo HC. Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Neurourol Urodyn. 2018. This clinical trial revealed that subjective improvement was reported in 61.1% of patients with voiding dysfunction due to urethral sphincter hyperactivity after onabotulinumtoxinA urethral sphincter injection. An open bladder neck during voiding at baseline predicts a successful outcome.
  53. 53.
    Liao YM, Kuo HC. Causes of failed urethral botulinum toxin A treatment for emptying failure. Urology. 2007;70:763–6.CrossRefGoogle Scholar
  54. 54.
    Reitz A, Schmid DM, Curt A, Knapp PA, Schurch B. Afferent fibers of the pudendal nerve modulate sympathetic neurons controlling the bladder neck. Neurourol Urodyn. 2003;22:597–601.CrossRefGoogle Scholar
  55. 55.
    Osman NI, Chapple CR. Fowler’s syndrome – a cause of unexplained urinary retention in young women? Nat Rev Urol. 2014;11:87–98.CrossRefGoogle Scholar
  56. 56.
    Chang YH, Siu JJ, Hsiao PJ, Chang CH, Chou EC. Review of underactive bladder. J Formos Med Assoc. 2018;117:178–84.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Urology, Buddhist Tzu Chi General HospitalTzu Chi UniversityHualienTaiwan

Personalised recommendations